SU1435255A1 - Method of recovering antithromogenic activity of vessel wall of cardiological patients - Google Patents
Method of recovering antithromogenic activity of vessel wall of cardiological patients Download PDFInfo
- Publication number
- SU1435255A1 SU1435255A1 SU864138206A SU4138206A SU1435255A1 SU 1435255 A1 SU1435255 A1 SU 1435255A1 SU 864138206 A SU864138206 A SU 864138206A SU 4138206 A SU4138206 A SU 4138206A SU 1435255 A1 SU1435255 A1 SU 1435255A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- activity
- anticoagulant
- vascular wall
- index
- days
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относитс к медицине. Дл повышени антикоагул нтной активности сосудистой стенки кардиологическим больным ввод т курантил, глютаминовую кислоту и фитин в общеприн тых дозах в течение 12-20 дн.This invention relates to medicine. In order to increase the anticoagulant activity of the vascular wall, chimes, glutamic acid and phytin were administered to cardiac patients in standard doses for 12–20 days.
Description
4four
оо ел юoo ate yu
СПSP
сдsd
Изобретение относитс к медицине и может быть использовано при лечении сердечно-сосудистых заболеваний.This invention relates to medicine and may be used in the treatment of cardiovascular diseases.
Цель изобретени - повышение анти- коагул нтной активности сосудистой стенки.The purpose of the invention is to increase the anticoagulant activity of the vascular wall.
Пример 1. У больной А., 56 лет, диагноз: ишемическа болезнь сердца, стабильна стенокарди напр жени , функциональный класс II, недостаточность кровообращени О, атеросклеротический кардиосклероз.Example 1. Patient A., 56 years old, diagnosed with ischemic heart disease, stable angina, functional class II, circulatory insufficiency O, atherosclerotic cardiosclerosis.
При поступлении индекс антикоагул нт- ной активности 0,9; фибринолитической 0,6. В течение J2 дн больной получал традиционную терапию: сустак по 2,6 мг три раза в день, анаприлин по 10 мг три раза в день.When entering the index of anticoagulant activity of 0.9; fibrinolytic 0.6. For J2 days, the patient received traditional therapy: sustak 2.6 mg three times a day, inderal 10 mg three times a day.
В течение последующих 12 дн больной получал курантил, глутаминовую кислоту и фитин в общеприн тых дозах. После проведенного лечени индекс антикоагул нт- ной активности составл л 1,06; фибринолиПроведен двухнедельный курс лечени Ютической 1,88. В норме индекс антикоагукурантилом по 0,025 г 3 раза в день, глута-л нтной активности составл л 1,2-1,4; фибминовой кислотой по 0,25 г три раза в деньринолитической 1,2-2,2.Over the next 12 days, the patient received chimes, glutamic acid and phytin in conventional doses. After treatment, the index of anticoagulant activity was 1.06; fibrinoli A two-week course of treatment with Uticheskaya 1.88 was performed. Normally, the anticoagurant index was 0.025 g 3 times a day, the glutaline activity was 1.2-1.4; Fibminic acid 0.25 g three times a daynolytic 1.2-2.2.
и фитином по 0,25 г три раза в день per os.Использование изобретени позволитand phytin 0.25 g three times a day per os.Using the invention will allow
повысить эффективность лечени заболеваДо и после лечени определ ют антикоа- ний, в патогенезе которых имеетс уменьшегул нтную активность сосудистой стенки,ние антикоагул нтной и фибринолитической при этом индекс антикоагул нтной активности до лечени составл ет 0,96, фибринолитической 0,75. После лечени индекс антикоагул нтной активности составл ет 1,17,20to increase the efficiency of treatment of the disease and after treatment, anticoagies are determined, in the pathogenesis of which there is a decrease in vascular wall activity, anticoagulant and fibrinolytic activity, while the index of anticoagulant activity before treatment is 0.96, fibrinolytic 0.75. After treatment, the index of anticoagulant activity is 1.17.20
активности сосудистой стенки.vascular wall activity.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU864138206A SU1435255A1 (en) | 1986-10-20 | 1986-10-20 | Method of recovering antithromogenic activity of vessel wall of cardiological patients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU864138206A SU1435255A1 (en) | 1986-10-20 | 1986-10-20 | Method of recovering antithromogenic activity of vessel wall of cardiological patients |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1435255A1 true SU1435255A1 (en) | 1988-11-07 |
Family
ID=21264123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU864138206A SU1435255A1 (en) | 1986-10-20 | 1986-10-20 | Method of recovering antithromogenic activity of vessel wall of cardiological patients |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU1435255A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2725626C2 (en) * | 2013-03-15 | 2020-07-03 | Лабораторис Санифит, С. Л. | Use of derivatives containing the c-o-p bonds in the patients with renal insufficiency |
-
1986
- 1986-10-20 SU SU864138206A patent/SU1435255A1/en active
Non-Patent Citations (1)
Title |
---|
Лакин К. М.,Чазов Е. И. Аитикоагул нты и фибринолитические средства. М.: Медицина. 1977, с. 3. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2725626C2 (en) * | 2013-03-15 | 2020-07-03 | Лабораторис Санифит, С. Л. | Use of derivatives containing the c-o-p bonds in the patients with renal insufficiency |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kelly et al. | Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities | |
US4075352A (en) | Method of improving the myocardial function by the administration of carnitine | |
Roubin et al. | Intravenous nitroglycerine in refractory unstable angina pectoris | |
Binder et al. | Paroxysmal ventricular tachycardia and fibrillation due to quinidine | |
Hebb et al. | A new beta adrenergic blocking agent, propranolol, in the treatment of angina pectoris. | |
Johansson et al. | Hereditary prolongation of QT interval. | |
SU1435255A1 (en) | Method of recovering antithromogenic activity of vessel wall of cardiological patients | |
Hall et al. | Cardiac lesions in adrenal insufficiency | |
O'Reilly et al. | " Cope's sign" and reflex bradycardia in two patients with cholecystitis. | |
US4400371A (en) | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats | |
Peters et al. | Continuous intravenous administration of histamine: effect on the electrocardiogram and serum potassium | |
Danta et al. | Multiple emboli from left ventricular myxoma. | |
SU1292730A1 (en) | Method of determining the indication to use of calcium antagonists for patients ill with ischemia heart disease | |
SU789109A1 (en) | Method of treating children's active rheumatism | |
SU1173381A1 (en) | Method of ischemic heart disease simulation | |
SU1007674A1 (en) | Method of treating extrasystolic arrythmia of children | |
Allon et al. | Prolonged hypotension after initial minoxidil dose | |
SU1399679A1 (en) | Method of determining individual sensitivity to antianginal preparations of cardiac ischemic disease patients | |
Welman et al. | The Effect of Established β-Adrenoreceptor-Blocking Therapy on the Release of Cytosolic and Lysosomal Enzymes after Acute Myocardial Infarction in Man | |
SU1418803A1 (en) | Method of simulating postinfarction cardiac aneurism | |
SU1392644A1 (en) | Method of simulating acute postinfarction cardiac aneurysm | |
RU1777880C (en) | Method for treatment of infarction of myocardium | |
SU1491515A1 (en) | Method of treating non-rheumatic miocardites | |
RU1803876C (en) | Method of preoperative preparation of children with congenital heart disease | |
RU1802341C (en) | Method of myocardial infarction diagnosis |